Medical Communications

Early and managed access programmes provide opportunities for patients to get the treatments they need faster – but the COVID-19 …

COVID-19 news has slowed down in the last week, allowing different pharma developments to take centre stage. In the last …

GlaxoSmithKline’s (GSK) Phase II OSCAR study of their otilimab antibody’s effect on COVID-19 patients has shown promising results in older …

The race to provide vaccines and treatments for coronavirus has seen a number of COVID-19 drugs reach the market in …

NICE has recommended Novartis’ Kisqali (ribociclib) in combination with fulvestrant for women with prior endocrine therapy. It will be made …

MSD, known as Merck in the United States and Canada, has announced that it will acquire clinical-stage biotechnology company Pandion …

Takeda has entered into an agreement to transfer the assets, marketing rights, and, eventually, marketing authorisation associated with a portfolio …

In the last week, a number of COVID-19 new vaccine developments have been made. Pfizer and BioNTech’s vaccine has proven …

Cell Guidance Systems’ new POlyhedrin Delivery System (PODS) technology has been shown to have therapeutic potential in the treatment of …

Cascade Chemistry, a leading pharmaceutical contract development and manufacturing organisation, has initiated the $14 million construction of new facilities to …

Dermavant Sciences has announced positive safety and efficacy results from a planned interim analysis of PSOARING 3, a long-term, open-label …

RedHill Biopharma has announced agreements with Cosmo Pharmaceuticals to manufacture two of RedHill’s key products. Cosmo will manufacture Movantik, RedHill’s …

Over the past week, AstraZeneca’s COVID-19 jab has been at the centre of disputes about vaccine efficiency both in older …

NICE has issued final draft guidance recommending the routine use of Bristol Myers Squibb (BMS)’s Opdivo (nivolumab) as an option …

Several European countries have continued to impose age restrictions on their rollouts of the Oxford University-AstraZeneca vaccine, despite WHO’s repeated …